Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Considers The Value Of Insider Participation In Biotech IPOs

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by Radius Health, Cempra, Ironwood and Acetylon.

You may also be interested in...



Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public

Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.

HDAC Inhibitor Mysteries Remain As Candidates Advance

With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.

Second Tranche Of $91 Million Venture Round Will Help Advance Two Formulations Of Radius’ Osteoporosis Drug

Radius, which reverse-merged into a public company this past May, has advanced an injectable formulation of BA058 into Phase III, while it is preparing to move a transdermal version into Phase II.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel